ClinicalTrials.gov record
Terminated Phase 1 Interventional

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

ClinicalTrials.gov ID: NCT00052884

Public ClinicalTrials.gov record NCT00052884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis

Study identification

NCT ID
NCT00052884
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eastern Cooperative Oncology Group
Network
Enrollment
8 participants

Conditions and interventions

Interventions

  • amifostine trihydrate Drug
  • bone marrow ablation with stem cell support Procedure
  • filgrastim Biological
  • melphalan Drug
  • peripheral blood stem cell transplantation Procedure

Drug · Procedure · Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 21, 2004
Primary completion
Aug 31, 2007
Completion
Feb 28, 2011
Last update posted
Jun 17, 2023

2004 – 2011

United States locations

U.S. sites
16
U.S. states
4
U.S. cities
15
Facility City State ZIP Site status
Mayo Clinic Scottsdale Scottsdale Arizona 85259-5499
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202-5289
Fairview Ridges Hospital Burnsville Minnesota 55337
Mercy and Unity Cancer Center at Mercy Hospital Coon Rapids Minnesota 55433
Fairview Southdale Hospital Edina Minnesota 55435
Mercy and Unity Cancer Center at Unity Hospital Fridley Minnesota 55432
Minnesota Oncology Hematology, PA - Maplewood Maplewood Minnesota 55109
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital Minneapolis Minnesota 55407
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center Robbinsdale Minnesota 55422-2900
Mayo Clinic Cancer Center Rochester Minnesota 55905
CCOP - Metro-Minnesota Saint Louis Park Minnesota 55416
Park Nicollet Cancer Center Saint Louis Park Minnesota 55416
United Hospital Saint Paul Minnesota 55102
Ridgeview Medical Center Waconia Minnesota 55387
Minnesota Oncology Hematology, PA - Woodbury Woodbury Minnesota 55125
Case Comprehensive Cancer Center Cleveland Ohio 44106-5065

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00052884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2023 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00052884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →